Thrombosis Research (2005) 116, 545–550

ELSEVIER

THROMBOSIS RESEARCH

intl.elsevierhealth.com/journals/thre

Author Index—Volumes 115-116 (2005)

Abaci, A., 116:465
Abe, Y., 115:271; 116:307
Abeyama, K., 115:319
Abildgaard, U., 115:519
Abrahamsson, T.I., 116:519
Ageno, W., 116:301
Agnelli, G., 116:301
Agnese, A.M., 115:494
Ahmed, R.P.H., 115:535
Aizawa, Y., 115:219
Akar, N., 115:159, 393
Akin, M., 116:287
Aksu, K., 115:287
Al Yemeni, E., 116:377
Alfonso, F., 115:101; 116:491
Almanric, K., 116:41
Almsherqi, Z.A., 116:451
Altieri, P., 115:65
Alves-Filho, J.C.F., 115:537
Amato, S., 116:443
Ambrosio, G.B., 116:301
Ammannati, F., 115:405
Anand, S., 115:491
Andresen, M.S., 115:519
Angiolillo, D.J., 115:101; 116:491
Antovic, A., 116:509
Aoki, N., 116:455
Aoyagi, K., 115:271
Arnesen, H., 115:163, 257; 116:313
Astermark, J., 116:15
Atalay, F., 115:159
Aurigemma, C., 116:25
Ayaz, S., 115:25
Aydin, H.H., 115:287
Aznar, J., 115:263, 399; 116:447

Bach, J., 116:33
Badar, J., 116:55
Bae, O.-N., 116:157
Bai, X., 116:385
Baier, K., 115:135
Balbay, Y., 115:25
Balbi, M., 115:65
Bang, N.U., 115:73
Bañuelos, C., 115:101; 116:491
Barnes, T.A., 115:461
Barrera-Ramirez, C., 115:101
Barsotti, A., 115:65
Bartok, A., 115:469
Baskin, E., 115:185
Bass, T.A., 115:101; 116:491
Bayram, F., 116:465
Baz-Hecht, M., 116:1
Bazinet, A., 116:41
Bazzan, M., 116:301
Beaulieu, E., 115:143
Bégaud, B., 115:31
Beight, D.W., 116:265
Béliveau, R., 115:143
Bene, J., 116:479
Berdeli, A., 116:287
Berggren, M., 116:249
Berloco, P., 116:471
Bernardo, E., 115:101; 116:491
Berntorp, E., 116:15
Bersi, C., 116:207
Bertero, G., 115:65
Bertoldi, A., 116:301
Bertsch, T., 116:171
Bhattacharya, M., 115:534
Biswas, A., 115:535
Björkman, J.-A.E., 116:519
Bjørn, S.E., 116:75
Blais, N., 116:41
Blann, A.D., 115:205; 116:181, 377
Blessing, F.J., 115:39
Bliden, K.P., 115:89
Blombäck, M., 116:509
Boehlen, F., 115:131
Boisseau, M., 115:31
Boivin, D., 115:143
Boman, K., 116:249
Boneu, B., 116:293
Bordet, J.C., 116:483
Borensztajn, K., 116:115
Branner, S., 116:75
Brennan, S.O., 115:293
Brenner, B., 116:109
Broberg, A., 116:249
Broekman, M.J., 116:199
Brunelli, C., 115:65
Brunet, C., 116:41
Bruno, A., 115:73
Budihna, M.V., 115:527

Cabrera, J.L., 115:495
Cadroy, Y., 116:293
Cagirgan, S., 115:287
Caldir, V., 115:25
Calevo, M.G., 116:443
Caliskan, M., 116:465
Calvo, J., 115:399
Cam, S.F., 116:287
Carlsson, S.C., 115:9
Carmassi, F., 116:207
Caron, S., 116:41
Carroll, R.C., 116:51
Cavallari, U., 116:491
Celik, H.A., 115:287
Cengiz, N., 115:185
Cerbone, A.M., 115:439
Černe, M., 115:526
Cetin, M., 116:465
Cetin, S., 116:465
Chafa, O., 116:115
Chandler, W.L., 115:327
Chang, G.-T., 116:421

0049-3848/$ - see front matter © 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/S0049-3848(05)00386-5

Chang, T.-S., 115:309
Chen, C., 115:417
Chen, C.-Y., 115:153
Chesebro, J.H., 116:525
Chiang, T.M., 115:503
Chin, B.S.P., 116:181
Choi, E.-Y., 116:421
Chong, A.Y., 116:181
Christensen, J.H., 115:257
Christensen, K., 115:245
Chung, I., 116:275
Chung, J.-H., 115:309; 116:157
Chung, K.-H., 116:421
Chung, K.-Y., 116:157
Chung, S.-M., 116:157
Cirillo, F., 115:439
Cohen, S.N., 115:73
Colucci, M., 116:471
Contreras, M.T., 115:399
Cooley, B.C., 115:153
Coppola, A., 115:439
Corella, D., 115:399
Cosman, F., 116:1
Costa, M.A., 115:101; 116:491
Covic, L., 116:55
Crea, F., 116:25
Crowther, M.A., 115:3
Cruz, J.D., 116:1
Cullinane, A.M., 116:499
Cushman, M., 116:1
Cvirn, G., 115:135

Dally, N., 116:109
Dampier, K., 115:461
Dargaud, Y., 116:483
Datta, Y., 115:153
De Boer, R.A., 116:279
De Caterina, R., 115:163, 257
De Faire, U., 116:223
De Giorgi, A., 116:207
De Moerloose, P., 115:131
De Negri, F., 116:207
De Simone, C., 115:439
Dechavanne, M., 116:483
Deda, G., 115:393
DeLa Cadena, R.A., 116:533
Dell'Omo, G., 116:207
Dempfle, C.-E., 116:171
Deng, G., 115:341
Deng, Y., 116:451
Denis Alexander, H., 115:109
Deol, P.S., 115:461
Depont, F., 115:31
Devoto, E., 115:65
Di Leo, A., 116:471
Do, Y.H., 116:265
Doganavsargil, E., 115:287
Dogné, J.-M., 116:431
Dole, W.P., 115:341
Donmez, A., 115:287
D'Orio, V., 116:431
Dorn-Beineke, A., 116:171
Drevenšek, G., 115:526
Drion, P., 116:431
Drosopoulos, J.H.F., 116:199

Ekman, G.J., 116:509
Elder, R.F., 116:51
Elgue, G., 115:245
Elhan, A.H., 115:393
Eliasson, Å., 115:9
Elm, T., 116:75
El-Omar, M.M., 116:199
Emanuelsson, H., 115:245
Emi, Y., 116:215
Endo, S., 116:357
Ercan, E., 116:287
Eriksson, U.G., 115:9
Ernam, D., 115:159
Escaned, J., 115:101, 116:491
España, F., 115:399

Fattal-Valevski, A., 116:133
Fernandez-Ortiz, A., 115:101; 116:491
Ferrando, F., 116:447
Fioriti, R., 116:207
Fischer, A.-M., 116:115
Fischer, J.E., 115:175
Fischler, B., 116:185
Fisher, M., 115:435
For the Warfarin Optimal Duration Italian Trial (WODIT) Investigators, 116:301
Forslund, M., 116:241
Francis, C., 115:1
Frederick, M., 115:327
Friedman, K.D., 115:153
Fruzzetti, F., 116:207
Fujikawa, K., 115:441
Funahashi, T., 115:483
Fuse, I., 115:219

Gabriel, F., 115:263
Gallistl, S., 115:135
Gando, S., 116:91
García-Herola, A., 116:321
Garibaldi, S., 115:65
Gasztonyi, B., 116:479
Geisen, C., 115:534
Gende, O.A., 116:67
George, P.M., 115:293
Gerrits, W.B.J., 115:381
Ghigliotti, G., 115:65
Ghuysen, A., 116:431
Giannarelli, C., 116:207
Giddings, J.C., 116:393
Gifford-Moore, D.S., 116:265
Gilmore, W.S., 115:109
Gingras, D., 115:143
Ginsberg, J., 115:1
Glazier, G., 115:143
Goldenberg, N.A., 116:345
Golding, B., 116:335
Gorelick, P.B., 115:73
Grabowski, E.F., 116:409
Granlund, A., 116:249
Grill, D.E., 116:525
Guazzaloca, G., 116:301
Guglielmone, H.A., 115:495
Guiral, V., 115:263
Gumulec, J., 115:427
Guray, U., 115:25
Guray, Y., 115:25
Gurbel, P.A., 115:89

Haddad, N., 116:109
Hallqvist, J., 116:223
Hamasaki, N., 115:351
Hanson, J., 116:431
Hanson, S.R., 115:79
Harel, S., 116:133
Harish Kumar, M., 116:255
Hashiguchi, T., 115:319
Hashimoto, N., 116:215
Hassinger, N.L., 116:525
Hassner, A., 116:133
Hathaway, W.E., 116:345
Havasi, V., 116:479
Hayakawa, M., 116:91
Hayakawa, Y., 116:357
Hayashi, N., 116:357
He, S., 116:509
Held, P., 115:9
Hellstern, P., 116:33
Hemker, H.C., 115:255
Hennessey, M.D., 116:51
Heptinstall, S., 115:301
Hernández, R., 115:101; 116:491
Hillbom, M., 115:367
Hillege, H.L., 116:279
Hiller, E., 116:233
Hirashima, Y., 116:357
Hirokawa, T., 115:475
Hjemdahl, P., 116:509
Hjerkinn, E.M., 116:313
Hoffman, R., 116:109

Hokamaki, J., 115:483
Honda, O., 115:483
Horne III, M.K., 116:499
Hoshino, H., 116:91
Howley, H.E.A., 116:101
Hu, H., 116:241
Huang, H.-Y., 116:145
Huber, K., 115:469
Hudig, F., 115:381
Hursting, M.J., 116:121
Huwer, H., 116:33

Ichikawa, S., 115:359
Iida, H., 115:351
Ijiri, Y., 115:115
Ijiru, Y., 116:393
Ikarugi, H., 116:127, 403
Ikeda, T., 116:215
Ikeda, Y., 115:191
Imanaka, T., 116:215
Imberti, D., 116:365
Inal, V., 115:287
Infusino, F., 116:25
Ingelfinger, J.R., 116:409
Inman, J., 116:335
Inoue, A., 116:127, 403
Inoue, S., 115:351
Ishii, H., 116:127, 403
Ishii, K., 115:191
Ishikura, K., 115:53; 116:307
Isik Agras, P., 115:185
Islam, N., 116:199
Isordia-Salas, I., 116:533
Iwamoto, H., 115:319
Iwasaka, T., 115:277
Iwata, M., 115:211

Jacobson, A., 115:45
Jacobson, L., 116:345
Jacques, S., 116:55
Jacquet, A., 115:31
Jaeger, B., 115:39
Jäger, U., 115:59
Jansen, R.W., 115:381
Jansson, J.-H., 116:249
Jetzl, A., 115:469
Ji, S., 116:385
Jiang, M., 116:385
Jimenez-Quevedo, P., 116:491
Johnston, M., 115:427
Jones, S.W., 115:341
Juvela, S., 115:367

Kalnoski, M.H., 115:327
Kalweit, G., 116:33
Kameue, T., 116:91
Kamikura, Y., 115:53; 116:307
Kang, H.-M., 115:327
Kannan, M., 115:534
Karahan, Z.C., 115:393
Karalis, I., 116:377
Kario, K., 115:475
Karlson, B.W., 115:9
Katayama, K., 116:215
Katayama, M., 116:215
Kathriner, S., 116:165
Kato, H., 116:91
Katori, N., 115:79
Kavlie, A., 116:313
Kawano, H., 115:483
Kazahaya, Y., 115:53
Kelly, A.B., 115:79
Kelton, J.G., 116:121
Kenet, G., 116:133
Kerényi, A., 116:139
Keser, G., 115:287
Khil, L.-Y., 115:309
Kim, C.-H., 116:421
Kim, D., 115:309
Kim, J.A., 115:435
Kim, J.-H., 116:421
Kim, Y.-C., 115:309
Kimmelstiel, C., 116:55
Kinoshita, S., 115:351
Kirazli, S., 115:185
Kirszberg, C., 115:123
Kitagawa, A., 115:483
Kitajima, I., 116:215
Kitamari, K., 116:127
Klement, P., 115:427
Kliber, A., 115:491
Klimkowski, V.J., 116:265
Knöbl, P., 115:59
Kobayashi, T., 116:307
Koestenberger, M., 115:135
Kojima, S., 115:483
Kolb, H.J., 116:233
Kolh, P., 116:431
Komlósi, K., 116:479
Kono, M., 115:271
Kopp, C.W., 115:469
Korkmaz, S., 115:25
Koschinsky, M.L., 115:491
Kotze, H., 115:79
Krishna Biswas, K., 115:319
Kristensen, S.D., 115:163, 257
Kroner, C., 116:327
Kudielka, B.M., 115:175
Kuliopulos, A., 116:55
Kumakura, H., 115:359
Kupferminc, M.J., 116:133
Kurabayashi, M., 115:359
Kurihara, M., 115:351
Kurimoto, M., 116:357
Kushak, R.I., 116:409
Kuwayama, N., 116:357

Labiós, M., 115:263
Lalonde, L., 116:41
Lamassa, M., 115:405
Lambermont, B., 116:431
Lambert, J., 116:409
Lane, J.R., 115:45
Lanza, G.A., 116:25
Larosa, C., 116:25
Larsson, A., 115:245
Larsson, R., 115:245
Le Bonniec, B., 116:115
Leander, K., 116:223
Lechner, K., 115:59
Lee, B.-H., 115:309
Lee, G.-Y., 115:309
Lee, K.-S., 115:309
Lee, M.-Y., 116:157
Lee, S.-J., 116:157
Lehr, S., 115:59
Leitner, Y., 116:133
Leschnik, B., 115:135
Lethagen, S., 116:15
Lewis, B.E., 116:121
Li, N., 116:241
Liang, A., 115:341
Liestøl, S., 115:509
Lignot, S., 115:31
Lin, P., 115:417
Lindman, A.S., 116:313
Lindsay, R., 116:1
Lip, G.Y.H., 115:171, 205; 116:181, 275, 321, 377
Liu, C.-Z., 116:145
Liu, Y., 115:319
Lorin, J.D., 116:199
Lu, D., 116:265
Lumsden, A.B., 115:417

Macaya, C., 115:101; 116:491
Maccallini, A., 116:25
MacFadyen, R.J., 115:205
Maghzal, G.J., 115:293
Magis, D., 116:431
Makris, M., 115:451
Małyszko, J., 115:19
Małyszko, J.S., 115:19
Manco-Johnson, M.J., 116:345
Manns, J.M., 116:533
Marcus, A.J., 116:199
Marín, F., 116:321
Mariotti, F., 115:405

Marroni, A.S., 115:375
Marsh, J.J., 115:45
Martineau, J., 116:41
Martínez, E., 115:263
Martínez, M., 115:263
Maruyama, I., 115:319
Maruyama, M., 116:255
Maruyoshi, H., 115:483
Marzec, U., 115:79
Maser, E., 116:101
Masereel, B., 116:431
Matsuda, M., 115:53
Matsuda, N., 116:91
Matsumoto, T., 115:53
Matsuo, T., 115:475
Matsuzawa, Y., 115:483
Matthai Jr., W.H., 116:121
Mattsson, C., 115:9
Mattsson, C.J., 116:519
May, J.A., 115:301
Mazet, M., 116:483
McBane II, R.D., 116:525
McConnell, J.P., 115:73
McGlynn, H., 115:109
Mclachlan, C., 116:451
Melegh, B., 116:479
Melegh, G., 116:479
Mello, G., 115:405
Mennonna, P., 115:405
Merchlinsky, M., 116:335
Merryman, P.K., 116:499
Mesterman, R., 116:133
Metzger, I.F., 115:375
Miall, F.M., 115:461
Middeldorp, J.M., 115:387
Minar, E., 115:469
Minematsu, K., 115:455
Mira, Y., 116:447
Mischke, R., 115:229
Mischler, K., 115:175
Miyamoto, S., 115:483
Moia, M., 116:301
Molinari, A.C., 116:443
Monteiro, R.Q., 115:123
Moon, C.-H., 115:309
Moon, C.-K., 115:309
Moore, N., 115:31
Moreno, R., 115:101; 116:491
Moreno-Aspitia, A., 116:87
Moriki, T., 115:191
Morris, T.A., 115:45
Morser, J., 115:341
Mossop, P.J., 116:451
Mózsik, G., 116:479
Mruk, J.S., 116:525
Muenchen, R.A., 116:51
Muntean, W., 115:135
Muradin, A.A., 115:381
Murata, M., 115:191
Muszbek, L., 116:139
Myśliwiec, M., 115:19

Nadar, S.K., 116:377
Nádasi, E., 116:479
Naemura, A., 115:115
Nagassaki, S., 115:375
Nakamura, T., 115:211
Nakano, T., 115:53, 211, 116:215, 307
Nan, B., 115:417
Naritomi, H., 115:455
Negrier, C., 116:483
Nemeth, A., 116:185
Nerme, V.K., 116:519
Nestoridi, E., 116:409
Nieves, D.R., 115:1
Nieves, J.W., 116:1
Nilsson, G., 116:15
Nilsson, T.K., 116:249
Nishiguchi, M., 115:271
Nishikawa, M., 115:277; 116:307
Nishioka, J., 116:307
Niwano, H., 115:219
Nobori, T., 115:53; 116:307
Nomura, S., 115:277; 116:215
Nørby, P.L., 116:75
Nordenhem, A., 116:223
Núñez Montoya, S.C., 115:494

Oda, E., 115:115, 116:393
Ogawa, H., 115:483
Oguchi, S., 115:191
Oh, J.-Y., 116:421
Ohmori, T., 115:409
Okada, Y., 116:403
Ökten, F., 115:159
Oldenburg, J., 115:534
Olson, K.E., 116:199
Olwill, S.A., 115:109
Omay, S.B., 115:287
Omoto, S., 115:277
Omura, S., 116:255
On behalf of HIT Research Group of Japan, 115:475
Ono, M., 115:351
Oppenheimer, C.A., 115:461
Osada, M., 115:409
Owers, R.L., 116:51
Ozaki, Y., 115:409
Ozawa, T., 116:215
Ozbek, N., 115:185

Palmieri, N.M., 115:439
Papp, E., 116:479
Parekh, H., 116:533
Parretti, E., 115:405
Pasi, K.J., 115:461
Patteson, S.K., 116:51
Pavord, S.R., 115:461
Pchelina, S.N., 115:199
Pedersen, J.I., 116:313
Pedrinelli, R., 116:207
Peng, L., 115:427
Penovici, M., 116:233
Pentimone, A., 116:471
Perneby, C., 116:509
Persson, E., 116:75
Perutelli, P., 116:443
Pétein, M., 116:431
Peternel, L., 115:527
Petersen, L.C., 116:75
Petrini, P., 116:185
Pettersson, M., 116:185
Pignatti, P.F., 116:491
Pihusch, M., 116:233
Pihusch, R., 116:233
Pihusch, V., 116:233
Pirotte, B., 116:431
Prandoni, P., 116:301
Preckel, D., 115:175
Prisco, D., 116:365
Provençal, M., 115:143
Pulte, E.D., 116:199
Pyhtinen, J., 115:367

Radha, K.S., 116:255
Rak, J., 115:427
Ramírez, C., 115:101; 116:491
Rasmussen, L.H., 115:163, 257
Ratel, D., 115:143
Rathnachalam, R., 116:265
Reber, G., 115:131
Rechner, A.R., 116:327
Reghis, A., 116:115
Ricart, J.M., 115:399
Richardson, D., 115:73
Rimon, E., 116:133
Riutta, A., 115:367
Riviello, C., 115:405
Roa, D.C., 116:199
Rodger, M.A., 116:101
Roldán, V., 116:321
Rolin, S., 116:431
Rosendaal, F.R., 115:387
Ross, C.M., 116:273
Rossettin, P., 115:65
Rossiello, M.R., 116:471

Rowe, J.M., 116:109
Ruan, C., 116:385
Rumjanek, V.M., 115:123
Russo, F., 116:471
Rutten, W.P.F., 115:239

Saatci, U., 115:185
Sabaté, M., 115:101; 116:491
Sagcan, A., 116:287
Sainz, I., 116:533
Sakamaki, T., 115:359
Sakamoto, H., 115:359
Sakamoto, T., 115:483
Sakariassen, K., 116:293
Sakata, T., 115:455
Saloheimo, P., 115:367
Samara, W.M., 115:89
Sándor, J., 116:479
Sandset, P.R., 115:1
Sano, T., 115:115; 116:393
Santamaria, M.G., 116:301
Sarich, T.C., 115:9
Sarig, G., 116:109
Sase, T., 116:307
Sato, A., 116:127
Sato, N., 115:219
Sawada, Y., 115:359
Sawai, T., 115:53
Saxena, R., 115:535
Scherjon, S.A., 115:387
Schmidt, E.B., 115:163, 257
Schoon, H.-A., 115:229
Schulman, S., 116:185
Schwartz, E.I., 115:199
Sedlis, S.P., 116:199
Segers, P., 116:431
Segur, M.C., 115:31
Seidel, D., 115:39
Seidinger, D., 115:469
Seifried, E., 115:534
Seki, Y., 115:219
Sekuri, C., 116:287
Selig, M.K., 116:409
Seljeflot, I., 116:313
Semeraro, N., 116:471
Sestito, A., 116:25
Sgueglia, G.A., 116:25
Shah, A.K., 116:87
Sheth, S.B., 115:9
Shih, M.-H., 116:145
Shiku, H., 115:53, 116:307
Shindo, H., 115:271
Shouzu, A., 115:277
Shwarzman, A.L., 115:199
Silingardi, M., 116:301
Sipahi, T., 115:393
Sirotkina, O.V., 115:199
Snider, C.C., 116:51
Snider, R.M., 115:341
Soejima, H., 115:483
Soltész, P., 116:139
Sørensen, B.B., 116:75
Souza-Costa, D.C., 115:375
Spallarossa, P., 115:65
Sperr, W.R., 115:59
Štalc, A., 115:526
Stefenelli, T., 115:469
Stegnar, M., 115:526
Steiner, S., 115:469
Sten-Linder, M., 116:223
Stennicke, H.R., 116:75
Stiell, I., 116:101
Storey, R.F., 115:301
Sugiki, M., 116:255
Sugiyama, S., 115:483
Sumino, H., 115:359
Szegedi, G., 116:139
Szolnoki, Z., 116:479

Takahashi, H., 115:219
Takamura, N., 115:271
Takayama, Y., 115:359
Takeshita, E., 115:191
Talián, G., 116:479
Taliani, M.R., 116:301
Tanabe, N., 115:219
Tanaka, K.A., 115:79
Tanaka, Y., 116:215
Tantry, U.S., 115:89
Tanus-Santos, J.E., 115:375
Tapon-Bretaudière, J., 116:115
Taraskina, A.E., 115:199
Tayebjee, M.H., 115:205
Tchana-Sato, V., 116:431
Tengiz, I., 116:287
Thalamas, C., 116:293
Thøgersen, A.M., 116:249
Thrall, G., 115:171
Tietjen, G.E., 115:73
Tjeerdsma, G., 116:279
Toba, K., 115:219
Todolí, J., 115:399
Tomaru, T., 115:475
Tomasi, C., 116:301
Tombuloglu, M., 115:287
Tondi, F., 115:405
Tóth, K., 116:479
Trabetti, E., 116:491
Tran, K., 115:341
Tran, N.D., 115:435
Trzeciak, M.C., 116:483
Tsai, P.-J., 116:145
Tsuda, Y., 116:403
Tufano, A., 115:439
Turcotte, I., 116:41

Uchimura, T., 115:319
Uchiyama, S., 115:211
Umar, A., 115:31
Unal, A., 116:465
Uzuelli, J.A., 115:375

Valent, P., 115:59
Van den Besselaar, A.M.H.P., 115:239
Van der Meer, F.J.M., 115:387
Van Strijen, M.J.L., 115:381
Van Veldhuisen, D.J., 116:279
Vardy, M.D., 116:1
Varricchione, N., 115:439
Vavilova, T.V., 115:199
Vaya, A., 115:399, 116:447
Veierød, M.B., 116:313
Veres, K., 116:139
Verheugt, F.W.A., 116:279
Vermeer, H.J., 115:381
Vernersson, E., 116:15
Villa, P., 116:447
Vlasin, M., 115:427
Von Känel, R., 115:175

Wada, H., 115:53, 116:307
Wada, Y., 115:351
Wåhlander, K., 115:9
Wajcman, H., 116:115
Wakiyama, M., 115:351
Wallen, H.N., 116:509
Walli, A.K., 115:39
Wang, W., 116:335
Wang, X., 115:95
Wang, Y., 115:39, 319; 116:385
Warshawsky, A.M., 116:265
Waser, G., 116:165
Watanabe, K., 115:191, 351
Watson, C.C., 115:461
Waxman, S., 116:55
Weintraub, A., 116:55
Weitz, J.I., 115:427
Wells, P.S., 116:101
Weltermann, A., 115:59
Wijermans, P.W., 115:381
Wiman, B., 116:223
Winning, J., 116:33
Wisloff, F., 115:3
Wisløff, F., 115:509
Wisser, H., 116:171
Witsenburg, C.P.J., 115:387
Witteveen, E., 115:239

Wittmann, I., **116**:479
Wohlsein, P., **115**:229
Wu, F., **115**:341
Wu, Q., **115**:341
Wuillemin, W.A., **116**:165

Xiong, Y., **115**:211
Xu, L., **115**:95

Yamada, N., **115**:53; **116**:307
Yamaji, K., **115**:319
Yamakoshi, J., **115**:115
Yamamoto, H., **116**:357
Yamamoto, J., **115**:115, **116**:127, 393, 403
Yamashita, T., **115**:115; **116**:127, 393, 393, 403
Yamazaki, M., **115**:211
Yao, Q., **115**:417
Yasaka, M., **115**:455
Yatomi, Y., **115**:409
Ye, B., **115**:341
Yilmaz, M.B., **115**:25
Yilmaz, Y., **116**:465
Yoshida, E., **116**:255
Yoshimura, M., **115**:483
Ypma, P., **115**:381

Zgraggen, L., **115**:175
Zhao, Z., **115**:341
Zhou, W., **115**:435
Zhu, H., **116**:385
Zhu, J., **115**:503
Ziegler, S., **115**:59
Zion, M., **116**:1

Thrombosis Research (2005) 116, 551–555

ELSEVIER

THROMBOSIS RESEARCH

intl.elsevierhealth.com/journals/thre

Keyword Index—Volumes 115-116 (2005)

20210A, **115**:351
Acetylsalicylic acid, **116**:139, 293
Acquired factor V inhibitor, **116**:87
Activated clotting time, **115**:9
Activated FXII, **115**:65
Activated partial thromboplastin time, **115**:9
Activated protein C, **115**:319
Acute coronary syndrome, **115**:475
Acute coronary syndromes, **115**:65
Acute leukemia, **115**:59
Acute myeloid leukaemia, **115**:109
Acute promyelocytic leukemia, **116**:109
Adenovirus, **116**:357
Adhesion molecules, **115**:19; **116**:91
Adiponectin, **115**:483
ADP, **115**:31, **116**:55
Adult plasma, **115**:135
Advanced glycation end products, **115**:319
Age, **115**:205
Age-dependent, **116**:127
Aggregation, **115**:89
Animal model, **115**:95; **116**:335
Annexin II, **115**:109
Anti coagulant therapy, **116**:279
Anti platelet therapy, **116**:279
Anticoagulant, **116**:41
Anticoagulant protein, **116**:421
Anticoagulants, **115**:245
Anticoagulation, **115**:45, **116**:121
Antigen, **116**:307
Antioxidant, **115**:417
Antiphospholipid antibodies, **115**:3
Antiphospholipid syndrome, **115**:405
Antiplatelet, **116**:293
Antiplatelet activity, **115**:495
Antiplatelet agent, **115**:309
Antithrombin, **115**:519, **116**:15, 171
Antithrombin deficiency, **116**:215
Antithrombotic, **115**:95, **116**:293
Antithrombotics, **115**:341
Anti-Xa activity, **116**:41
ApoE LDLR double knockout mouse, **116**:393
Aprotinin, **115**:327
Argatroban, **116**:121
Armagnac, **115**:31
Arterial thrombosis, **115**:95
ASA treatment, **116**:509
Aspirin, **115**:211, 367; **116**:465, 483
Aspirin resistance, **115**:25
Atherosclerosis, **115**:73, 482; **116**:393
Atorvastatin, **115**:263
ATRA, **116**:109
Atrial fibrillation, **116**:321
Autologous growth factor, **116**:87
Automation, **116**:171

B16F10 melanoma, **115**:123
Behçet's disease, **115**:159, 287, 399
Bleeding, **116**:109
Blood coagulation, **115**:175, 191
Blood coagulation disorders, **116**:15
Blood coagulation tests, **116**:9
Blood collection tube, **115**:239
Brazilin derivative, **115**:309
Bypass graft occlusion, **115**:39

C57BL/6 mice, **115**:115
Ca^{2+} mobilization, **115**:409
Calcium, **116**:241
Cangrelor, **115**:301
CAPD, **115**:19
Carboxypeptidase, **116**:499
Carboxypeptidase U, **116**:519
Cardiac thrombus, **115**:159
Cardiopulmonary bypass, **115**:327
Cardiopulmonary bypass surgery, **116**:33
Cardiovascular diseases, **116**:199
CD146, **115**:19
Cell cycle, **115**:219
Cell detachment, **116**:409
Cerebral cavernoma, **115**:405
Cerebral hemorrhage, **115**:367
Cerebral palsy, **116**:133
CHADS, **116**:321
Chemokine, **115**:277
Child, **116**:185
Children, **115**:185
Chloride-bicarbonate exchanger, **116**:67
Cholesterol, **115**:375
Cilostazol, **115**:211
Clopidogrel, **115**:89, 101; **116**:55, 293, 491

S0049-3848/$ - see front matter © 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/S0049-3848(05)00387-7

Coagulation, **115**:159, 359, 519; **116**:171, 345, 421
Coagulation activation and fibrinolysis markers, **116**:33
Coagulation factor V, **116**:533
Coagulation factors, **116**:75
Coagulation FVII, **116**:313
Collagen, **115**:503
Computer modeling, **115**:327
Contact activation, **116**:33
Coronary artery disease (CAD), **115**:469, 483
Copenhagen rat, **115**:153
Coronary artery thrombosis, **116**:519
Coronary disease, **116**:525
Coronary heart disease, **115**:163
C-reactive protein (CRP), **115**:482
Critical stenosis, **115**:427
CRM-negative, **115**:191
CTL epitope, **116**:335
Curcumin, **115**:417
Cyclo-oxygenase 1 deficiency, **116**:483
Cyclosporin A, **115**:219
CYP2C9 polymorphism, **115**:199

3D microscopy, **116**:509
D-dimer, **115**:53, 271
D-dimer testing, **116**:165
D-Dimer PLUS, **115**:381
Deep vein thrombosis, **115**:351, **116**:215, 301
Deep venous thrombosis, **115**:381, **116**:165
Deficiency, **115**:191
Diabetes, **116**:465
Diagnostic strategy, **116**:165
Dialysis, **115**:185
Diet, **116**:313
Dipyridamole, **115**:435
Dipyridamole, **116**:293
Direct thrombin inhibitor, **116**:121
Disseminated intravascular coagulation (DIC), **116**:91
Disseminated intravascular coagulation, **115**:536
Diurnal variation, **115**:205
Dog, **115**:229
DVT, **115**:53; **116**:307

Ecarin clotting time, **115**:9
Endocarditis, **116**:145
Endothelial cell damage, **115**:219
Endothelial cell, **115**:417
Endothelial cells, **116**:233, 409
Endothelial damage, **116**:181
Endothelial dysfunction, **116**:181
Endothelial function, **116**:207
Endothelial nitric oxide synthase (eNOS), **115**:375
Endothelial nitric oxide synthase, **116**:287
Endothelial protein C receptor, **115**:417
Endothelium, **115**:19, 435; **116**:199
Eptifibatide, **115**:79
E-selectin, **116**:181
Estrogen, **115**:359; **116**:1
Ethnicity, **115**:205
Exercise, **115**:205
Experimental model, **115**:527
Expression, **116**:75
Expression study, **115**:191
Extracellular matrix, **115**:205

Factor FVII deficiency, **116**:115
Factor II, **116**:133
factor V Leiden, **115**:351
Factor V leiden, **116**:133
Factor VIII, **115**:387, **116**:335
Factor Xa, **115**:123
Factor XI, **115**:441
Factor XII, **115**:191
Fibrates, **115**:293
Fibrin degradation products, **115**:229
Fibrin degradation products by granulocyte elastase, **115**:53
Fibrin degradation, **115**:143
Fibrin fibrinogen degradation products, **115**:381
Fibrin gel permeability, **116**:509
Fibrinogen, **115**:39, 293; **116**:145, 171, 241
Fibrinogen consumption, **115**:427
Fibrinogen degradation, **115**:143
Fibrinolusis, **115**:359
Fibrinolysis, **115**:109, 327, 341; **116**:207, 265, 345
Fibrinolytic enzyme, **115**:143
Fibroblasts, **116**:357
Fish consumption, **115**:163
Flaveria bidentis, **115**:495
Flow cytometry, **115**:263, **116**:241
Framingham, **116**:321
Function, **116**:465
FV Leiden mutation, **115**:519

Gastrointestinal haemorrhage, **116**:185
Gender, **115**:205
Gene analysis, **115**:351
Gene mutation, **116**:115
Gene polymorphism, **116**:287
Gene therapy, **116**:335
Global assay, **116**:345
Global fibrinolytic capacity, **115**:185
Global haemostatic tests, **116**:15
Glycoprotein IIb/IIIa, **115**:263, 503; **116**:145
Glycoproteins, **115**:245
GPVI, **115**:409
Graft occlusion, **115**:25

H. pylori infection, **116**:471
Haemangiosarcoma, **115**:229
Haemostasis, **115**:229; **116**:185
Healthy volunteers, **115**:31
Heart failure, **116**:181, 279
HELLP syndrome, **115**:387
Hematocrit, **115**:175
Hemodynamics, **116**:431
Hemophilia, **115**:441
Hemophilia A, **116**:335
Hemorheology, **115**:399
Hemorrhagic complication, **115**:455
Hemostasis, **115**:95, 367; **116**:1
Heparin, **115**:45, 153, 301, 475
Heparin cofactor II, **116**:357
Heparin neutralization, **115**:509
Heparin-induced thrombocytopenia, **115**:475; **116**:121
Heparin-mediated extracorporeal low-density lipoprotein precipitation, **115**:39
Hepatic sequestration, **115**:79
High sensitive C-reactive protein, **116**:249
High-density lipoprotein cholesterol (HDL-C), **115**:483
HL-60 cell line, **116**:533
Human neutrophil elastase, **116**:533

Human placenta protein, **116**:421
Human plasma, **116**:157
Human umbilical vein endothelial cells, **115**:219
Hypercoagulability, **115**:527
Hyperlipidemia, **115**:263
Hypertension, **115**:277, 359

IL-6, **115**:393
Impaired renal function, **116**:41
Infarction, **115**:73
Inflammation, **115**:417; **116**:533
In-frame deletion, **116**:215
Inherited bleeding disorder, **116**:115
Inhibitor, **115**:503
Inhibitors, **116**:525
INR, **115**:239
INR (international normalized ratio), **115**:131
Insulin resistance, **116**:207
Intensive care, **116**:15
Interleukin-6, **116**:357
Interobserver reliability, **116**:101
Intima-media thickness (IMT), **115**:482
Intracellular degradation, **116**:215
Intracellular pH, **116**:67
Intrauterine growth restriction, **115**:387
Iron deprivation, **116**:255
Iron overload, **116**:157
i-STAT System Portable Clinical Analyser, **115**:131

Laser-induced thrombosis, **115**:115
LDL oxidation, **116**:157
Leukocyte, **116**:307
Lewis rat, **115**:153
Lipid peroxidation, **115**:319
Lipoprotein (a), **115**:39
Liver diseases, **116**:185
Low molecular weight heparin, **115**:45, 509; **116**:41
Lupus anticoagulant assays, **115**:509
Lymphocytes, **116**:199
Lysine, **116**:499

Magnesium, **115**:239
Matrix metalloproteinases, **115**:205
Medical patients, **116**:365
Melagatran, **115**:135
Mental stress test, **116**:25
Metalloproteases, **115**:143
Microparticles, **116**:409
Mitomycin C, **115**:219
Monitoring, **115**:131
Monoclonal antibodies, **115**:245
Monocytes, **116**:471
Mortality, **116**:15
Mouse, **115**:95
mRNA, **116**:307
mRNA binding protein, **116**:255
mRNA stability, **116**:255
MTHFR, **116**:133
Multiple organ dysfunction syndrome (MODS), **116**:91
Murine factor VII, **116**:75
Mutation, **115**:191
Myocardial infarction, **116**:139, 223, 431
Myocardial ischemia, **116**:33

n−3, **116**:393
n−6, **116**:393
Nephrotic syndrome, **115**:19
Neutrophil, **116**:91
Nifedipine, **115**:277
Nitrate, **115**:375
Nitric oxide, **115**:375; **116**:403
Nitrite, **115**:375
Normalized screening/confirm ratio, **115**:509
Nucleotide substitution, **116**:215

Obesity, **116**:41
Octreotide, **116**:185
Oral anticoagulants, **115**:131, 199
Oral direct thrombin inhibitor, **115**:135
Oral direct thrombin inhibitors, **115**:9

P2 receptor, **115**:301
PAI-1, **115**:341; **116**:127, 223, 255
PAI-1 inhibitor, **115**:341
Partial thromboplastin time, **116**:171
Percutaneous coronary intervention (PCI), **115**:469
Percutaneous coronary intervention, **115**:475
Peripheral arterial disease, **115**:39
PFA-100, **116**:139
PFA-100 testing, **116**:483
Phage display, **116**:385
Pharmacogenetics, **115**:199
Pharmacokinetics, **115**:45
Phosphatidylserine, **115**:263
Phospholipase A_2, **115**:309
Physical examination, **116**:101
Plasma kallikrein inhibitor, **116**:403
Plasma thrombosis, **115**:73
Plasma volume, **115**:175
Plasminogen activator inhibitor-1, **116**:233
Plasminogen activator inhibitor-2, **116**:471
Plasminogen, **115**:109; **116**:499
Platelet, **115**:89, 409, 503; **116**:127, 145, 385, 465, 483
Platelet activation, **115**:211, 263; **116**:377
Platelet adhesion, **116**:377
Platelet aggregation, **115**:31, 309, 495, 503; **116**:241
Platelet aggregation inhibitors, **115**:301
Platelet function, **115**:115; **116**:491
Platelet membranes neutralization, **116**:421
Platelet reactivity, **115**:115; **116**:25
Platelets, **115**:101, 245, 301, 367, 536; **116**:55, 67, 139, 199, 233, 241, 403, 499, 525
Platelets Thrombin, **115**:441
Pneumatic tourniquet (tourniquet), **115**:271
Polycystic ovary syndrome, **116**:207
Polymerisation, **115**:293
Polymorphism, **116**:491
Polymorphisms, **115**:375; **116**:313
Polyphenols, **115**:31
Polyunsaturated fatty acid, **116**:393
Polyunsaturated fatty acids, **115**:163
Post-transcriptional regulation, **116**:255
Potentiation of platelet collagen activation, **116**:51

PP27, **116**:421
Prednisolone, **115**:219
Pre-eclampsia, **115**:387
Preeclampsia, **116**:51, 377
Pregnancy, **115**:293, 405, 461
Pregnancy related hypertension, **115**:387
Pregnancy-induced hypertension, **116**:377
Premature coronary artery disease, **116**:287
Pretest probability, **116**:101
Proanthocyanidin, **115**:115
Procoagulant effect, **116**:421
Procoagulant markers, **115**:277
Proexosite I, **115**:123
Prognostic factors, **115**:59
Prokaryotic expression, **116**:385
Promoter polymorphisms, **115**:393
Prophylaxis, **116**:365
Prostacyclin, **115**:367
Protein C, **115**:519; **116**:15
Protein kinase G inhibitor, **115**:435
Protein S, **115**:519
Prothombin fragment (F1.2), **115**:469
Prothrombin complex concentrate, **115**:455
Prothrombin time, **115**:9, 239; **116**:171
Prothrombinase complex, **115**:123; **116**:533
P-selectin, **115**:263; **116**:241, 377
Psychological stress, **115**:175
PT (prothrombin time), **115**:131
Pulmonary arterial aneurysms, **115**:159
Pulmonary embolism, **115**:381; **116**:101, 301
Pulmonary thromboembolism (PTE), **115**:271

Raloxifene, **116**:1
Randomized controlled clinical trial, **115**:31
Randomized trial, **116**:279
Rat, **115**:527
Reactive oxygen species, **115**:319
Recombinant factor VIIa (rFVIIa), **116**:185
Remnant-like particles, **115**:211
Resonance thrombography, **115**:229
Risk factor, **116**:127
Risk factors, **116**:365
Risk marker, **116**:223
rt-PA, **116**:519

Saphenous vein grafts, **115**:25
Sepsis, **115**:536; **116**:91
SERMs—Selective Estrogen Receptor Modulators, **116**:1
SF, **115**:53
Shark cartilage extract, **115**:143
Shear stress, **115**:211
Shear-stress, **115**:115
Sialic acid, **115**:293
Single chain Fv fragment, **116**:385
Soluble E-selectin, **116**:321
Specimen collection, **116**:249
Sphingosine 1-phosphate, **115**:409
Sphingosine kinase, **115**:409
Spirits, **115**:31
Spontaneous thrombolysis, **116**:127
STA Liatest, **116**:165
Stability, **116**:249
Stable angina, **115**:65; **116**:25
Staphylococcus aureus, **116**:145
Stasis, **115**:527
Statins, **115**:469
Stents, **115**:101, 245
Streptokinase, **116**:139
Streptokinase-induced arterial patency, **115**:427
Stroke risk stratification, **116**:321
Stroke, **115**:393
Structure and function of antithrombin, **115**:351
Sulphated flavonoids, **115**:495
Superoxide anions, **116**:157
Survival, **115**:59
Syndrome X, **116**:25
Systemic inflammatory response syndrome (SIRS), **116**:91

TAFI, **116**:265
TAFI and thrombosis, **115**:287
TAFIa, **116**:519
Tamoxifen, **116**:1
TF, **116**:307
Thiols, **116**:157
Thrombelastography, **115**:461
Thrombin, **115**:123; **116**:67, 525
Thrombin clotting time, **115**:9
Thrombin formation, **116**:33
Thrombin generation, **116**:483
Thrombocytopathy, **116**:483
Thrombocytopenia, **115**:79
Thromboembolism, **115**:3
Thrombogenesis, **116**:293
Thrombolysis, **115**:341; **116**:139, 403, 519
Thrombomodulin, **115**:417; **116**:181, 249, 471
Thrombophilia, **115**:461, 519; **116**:109, 133, 301
Thromboplastin antecedent, **115**:441
Thromboplastin, **115**:239; **116**:421
Thrombopoietin, **116**:51
Thrombosis, **115**:39, 101, 399; **116**:55, 121, 127, 199, 265, 403, 431, 525
Thrombospondin-1, **116**:533
Thromboxane, **115**:367
Thromboxane A_2, **115**:309
Thrombus, **116**:431
Tirofiban, **116**:55
Tissue factor, **116**:75, 233, 471
Tissue factor (TF), **115**:469; **116**:409
Tissue factor pathway inhibitor (TFPI), **115**:469; **116**:409
Tissue inhibitor of metalloproteinase, **115**:205
Tissue plasminogen activator, **115**:109, 435
Tissue-type plasminogen activator, **116**:357
TLR, **115**:536
TNF-α, **115**:393, 417
Total antioxidant capacity, **116**:157
Total knee arthroplasty (TKA), **115**:271
tPA, **116**:223
tPA-PAI-1 complex, **116**:249
Transforming growth factor beta-1, **116**:233

Triglycerides, **115**:65
Type 2 diabetes mellitus, **115**:277

Umbilical cord plasma, **115**:135
Unstable angina, **116**:25
Uteroplacental insufficiency, **115**:387

Vascular smooth muscle cells, **116**:357
Vasodilation, **116**:207
Veno-occlusive disease, **116**:233
Venous thromboembolism, **115**:59; **116**:301, 365
Venous thrombosis, **115**:527
Vessel injury, **115**:527
Vitamin K antagonists, **115**:131
Vodka, **115**:31
Von Willebrand factor, **116**:181, 321
Von Willebrands factor, **116**:249
VWF, **116**:385

Warfarin, **115**:3, 455; **116**:279
Warfarin therapy, **115**:199
Women, **115**:359

Ximelagatran, **115**:9, 135